Cowen analyst Joseph Thome reiterated an Outperform rating on Intellia Therapeutics (NASDAQ: NTLA), following report of additional data on NTLA-2001.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE